M. Bertrand, H. Rupprecht, P. Urban, and A. Gershlick, Double-Blind Study of the Safety of Clopidogrel With and Without a Loading Dose in Combination With Aspirin Compared With Ticlopidine in Combination With Aspirin After Coronary Stenting : The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS), Circulation, vol.102, issue.6, pp.624-633, 2000.
DOI : 10.1161/01.CIR.102.6.624

S. Yusuf, F. Zhao, and S. Mehta, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N Engl J Med, vol.345, pp.494-502, 2001.

S. Mehta, S. Yusuf, and R. Peters, Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study, The Lancet, vol.358, issue.9281, pp.527-560, 2001.
DOI : 10.1016/S0140-6736(01)05701-4

D. Angiolillo, A. Fernandez-ortiz, and E. Bernardo, Variability in Individual Responsiveness to Clopidogrel, Journal of the American College of Cardiology, vol.49, issue.14, pp.1505-1521, 2007.
DOI : 10.1016/j.jacc.2006.11.044

C. Frere, T. Cuisset, and P. Morange, Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome, The American Journal of Cardiology, vol.101, issue.8, pp.1088-93, 2008.
DOI : 10.1016/j.amjcard.2007.11.065

J. Collet, J. Hulot, and A. Pena, Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study, The Lancet, vol.373, issue.9660, pp.309-326, 2009.
DOI : 10.1016/S0140-6736(08)61845-0

J. Hulot, J. Collet, and J. Silvain, Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration, Journal of the American College of Cardiology, vol.56, issue.2, pp.134-177, 2010.
DOI : 10.1016/j.jacc.2009.12.071

C. Frére, T. Cuisset, B. Gaborit, M. Alessi, and J. Hulot, The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome, Journal of Thrombosis and Haemostasis, vol.79, issue.8, pp.1409-1420, 2009.
DOI : 10.1111/j.1538-7836.2009.03500.x

D. Sibbing, W. Koch, and D. Gebhard, Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement, Circulation, vol.121, issue.4, pp.512-520, 2010.
DOI : 10.1161/CIRCULATIONAHA.109.885194

S. Wiviott, E. Antman, and K. Winters, Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 Trial, Circulation, vol.111, issue.25, pp.3366-73, 2005.
DOI : 10.1161/CIRCULATIONAHA.104.502815

J. Brandt, C. Payne, and S. Wiviott, A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation, American Heart Journal, vol.153, issue.1, pp.9-16, 2007.
DOI : 10.1016/j.ahj.2006.10.010

S. Wiviott, E. Braunwald, and C. Mccabe, Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes, New England Journal of Medicine, vol.357, issue.20, pp.2001-2016, 2007.
DOI : 10.1056/NEJMoa0706482

J. Mega, S. Close, and S. Wiviott, Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes, Circulation, vol.119, issue.19, pp.2553-60, 2009.
DOI : 10.1161/CIRCULATIONAHA.109.851949

J. Brandt, S. Close, and S. Iturria, Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel, Journal of Thrombosis and Haemostasis, vol.26, issue.Suppl. 2, pp.2429-2465, 2007.
DOI : 10.1111/j.1538-7836.2007.02775.x

U. Schwarz, J. Geiger, U. Walter, and M. Eigenthaler, Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets: definition and detection of ticlopidine/clopidogrel effects, Thromb Haemost, vol.82, pp.1145-52, 1999.

L. Bonello, M. Pansieri, and J. Mancini, High On-Treatment Platelet Reactivity After Prasugrel Loading Dose and Cardiovascular Events After Percutaneous Coronary Intervention in Acute Coronary Syndromes, Journal of the American College of Cardiology, vol.58, issue.5, pp.467-73, 2011.
DOI : 10.1016/j.jacc.2011.04.017

R. Mehran, S. Rao, and D. Bhatt, Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium, Circulation, vol.123, issue.23, pp.2736-2783, 2011.
DOI : 10.1161/CIRCULATIONAHA.110.009449

D. Cutlip, S. Windecker, and R. Mehran, Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions, Circulation, vol.115, issue.17, pp.2344-51, 2007.
DOI : 10.1161/CIRCULATIONAHA.106.685313

K. Thygesen, J. Alpert, and H. White, WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction, Eur Heart J, vol.28, pp.2525-2563, 2007.

A. Michelson, A. Frelinger, . Iii, and E. Braunwald, Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial, European Heart Journal, vol.30, issue.14, pp.1753-63, 2009.
DOI : 10.1093/eurheartj/ehp159

D. Angiolillo, J. Badimon, and J. Saucedo, A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial, European Heart Journal, vol.32, issue.7, pp.838-884, 2011.
DOI : 10.1093/eurheartj/ehq494

D. Alexopoulos, I. Xanthopoulou, and P. Davlouros, Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel, American Heart Journal, vol.162, issue.4, pp.733-742, 2011.
DOI : 10.1016/j.ahj.2011.07.026

G. Parodi, B. Bellandi, and F. Venditti, Residual Platelet Reactivity, Bleedings, and Adherence to Treatment in Patients Having Coronary Stent Implantation Treated With Prasugrel, The American Journal of Cardiology, vol.109, issue.2, pp.214-222, 2012.
DOI : 10.1016/j.amjcard.2011.08.034

T. Cuisset, P. Morange, and M. Alessi, Recent advances in the pharmacogenetics of clopidogrel, Human Genetics, vol.345, issue.Suppl. 2, pp.653-64, 2012.
DOI : 10.1007/s00439-011-1130-6

T. Cuisset, C. Frere, and R. Poyet, Clopidogrel response: Head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting, Archives of Cardiovascular Diseases, vol.103, issue.1, pp.39-45, 2010.
DOI : 10.1016/j.acvd.2009.11.004

N. Breet, J. Van-werkum, and H. Bouman, Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation, JAMA, vol.303, issue.8, pp.754-62, 2010.
DOI : 10.1001/jama.2010.181

G. Montalescot, G. Sideris, and C. Meuleman, A Randomized Comparison of High Clopidogrel Loading Doses in Patients With Non???ST-Segment Elevation Acute Coronary Syndromes, Journal of the American College of Cardiology, vol.48, issue.5, pp.931-939, 2006.
DOI : 10.1016/j.jacc.2006.04.090

J. Rehmel, J. Eckstein, and N. Farid, INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450, Drug Metabolism and Disposition, vol.34, issue.4, pp.600-607, 2006.
DOI : 10.1124/dmd.105.007989

P. Roy, L. Bonello, and R. Torguson, Impact of ???Nuisance??? Bleeding on Clopidogrel Compliance in Patients Undergoing Intracoronary Drug-Eluting Stent Implantation, The American Journal of Cardiology, vol.102, issue.12, pp.1614-1621, 2008.
DOI : 10.1016/j.amjcard.2008.07.063

S. Armero, L. Bonello, and J. Berbis, Rate of Nuisance Bleedings and Impact on Compliance to Prasugrel in Acute Coronary Syndromes, The American Journal of Cardiology, vol.108, issue.12, pp.1710-1713, 2011.
DOI : 10.1016/j.amjcard.2011.07.038

G. Cayla, J. Hulot, O. Connor, and S. , Clinical, Angiographic, and Genetic Factors Associated With Early Coronary Stent Thrombosis, JAMA, vol.306, issue.16, pp.1765-74, 2011.
DOI : 10.1001/jama.2011.1529

G. Montalescot, G. Sideris, and R. Cohen, Prasugrel compared with high-dose clopidogrel in acute coronary syndrome, Thrombosis and Haemostasis, vol.103, issue.1, pp.213-236, 2010.
DOI : 10.1160/TH09-07-0482

D. Angiolillo, J. Saucedo, and R. Deraad, Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes, Journal of the American College of Cardiology, vol.56, issue.13, pp.1017-1040, 2010.
DOI : 10.1016/j.jacc.2010.02.072